Compare · IINN vs WST
IINN vs WST
Side-by-side comparison of Inspira Technologies Oxy B.H.N. Ltd. (IINN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IINN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.59B, about 1353.6x IINN ($16.7M).
- Over the past year, IINN is down 48.0% and WST is up 49.5% - WST leads by 97.5 points.
- IINN has been more active in the news (17 items in the past 4 weeks vs 5 for WST).
- WST has more recent analyst coverage (17 ratings vs 2 for IINN).
- Company
- Inspira Technologies Oxy B.H.N. Ltd.
- West Pharmaceutical Services Inc.
- Price
- $0.38+0.51%
- $334.67+4.58%
- Market cap
- $16.7M
- $22.59B
- 1M return
- -34.36%
- +2.67%
- 1Y return
- -47.97%
- +49.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 17
- 5
- Recent ratings
- 2
- 17
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest IINN
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing
- SEC Form F-3 filed by Inspira Technologies Oxy B.H.N. Ltd.
- Chief Technology Officer Yechezkely Hayon Daniella sold $150,000 worth of Ordinary Shares (50,000 units at $3.00), decreasing direct ownership by 6% to 780,000 units (SEC Form 4)
- Chief Financial Officer Tehila Yafit sold $105,019 worth of Ordinary Shares (30,000 units at $3.50) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 870,000 units (SEC Form 4)
- COO and VP of R&D Shabtay Abraham exercised 95,239 units of Ordinary Shares at a strike of $3.37, increasing direct ownership by 8% to 1,332,713 units (SEC Form 4)
- QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)